Actively Recruiting
Using Rapid Genetic Testing of CYP2C19 to Guide Blood Thinner Treatment After Acute Ischemic Stroke or Transient Ischemic Attack
Led by University of Virginia · Updated on 2026-05-06
350
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how to use a rapid genetic test to guide medication choices after an acute ischemic stroke or transient ischemic attack TIA. The study focuses on the CYP2C19 enzyme, which affects how well the blood thinner clopidogrel works in preventing another stroke. This observational study aims to find the best way to implement this genetic testing in a hospital setting and see if it changes doctors decisions on prescribing blood thinners. Participants will have a quick onsite genetic test that checks for 11 specific variations in the DNA related to the CYP2C19 enzyme. Doctors will receive the results to help decide whether to prescribe clopidogrel or a different blood thinner, like ticagrelor. The study will record how often patients are genotyped and how quickly results are available, along with the impact on treatment choices. During the study, patients will be monitored while receiving dual antiplatelet therapy, including assessments of their stroke-free status 90 days after the event. Researchers will also track adverse cardiovascular events and compare genetic test results with blood platelet function tests. The study involvement lasts from hospital admission through follow-up at 90 days, with data collected on medication changes, test turnaround times, and patient outcomes.
CONDITIONS
Brief Title
Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke
Research Team
A
Andrew Weko, MPH
R
Rachael M Stone, PharmD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here